ABSTRACT Mycoplasma gallisepticum (MG) is a major and economically significant pathogen of avian species. When administered before lay, F-strain MG (FMG) can reduce egg production during lay, but the ts-11 strain of MG (ts11MG) does not exert this effect. Two trials were conducted to determine the effects of pre-lay vaccinations of ts11MG, MG-Bacterin (MGBac), or their combination, in conjunction with an FMG vaccination overlay after peak production on the digestive and reproductive organ characteristics of HyLine W-36 layers housed in biological isolation units (4 units per treatment, 10 birds per unit). The following vaccination treatments were administered at 10 wk of age (woa): 1) Control (no vaccinations); 2) MGBac; 3) ts11MG; and 4) ts11MG and MGBac combination (ts11MG+MGBac). At 45 woa, half of the birds were vaccinated with a laboratory stock of high passage FMG. In both trials, parameters determined in 4 birds per unit at 55 woa included: BW; fatty liver hemorrhagic syndrome incidence; mean number of mature ovarian follicles; ovarian, oviduct, and small intestine weights; and the weights and lengths of the various portions of the oviduct and small intestine. Treatment effects were observed for the weights of the entire small intestine and the duodenum, jejunum, and ileum, as percentages of BW; and for vagina weight as a percentage of total oviduct weight. In general, the weights of the small intestine and its 3 components were increased in response to the FMG vaccine that was administered at 45 woa. An FMG vaccination at 45 woa may increase relative intestine weight in layers; however, use of a prelay MGBac vaccine alone or in combination with ts11MG, with or without an FMG overlay, does not affect the gross characteristics of their digestive and reproductive organs, and may be used without having an adverse effect on their performance, as was observed in a previous companion study.
INTRODUCTION
Mycoplasma gallisepticum (MG) remains a successful pathogen in layer flocks throughout the world (Jordan, 1975; Ley, 2003; Roussan et al., 2015) . Birds infected with this pathogen can exhibit various respiratory complications (Ley, 2003) and may experience a loss in productivity including decreases in egg production (Yoder and Hofstad, 1964; Patterson, 1994; Burnham et al., 2002a) and egg size (Branton et al., 1999) , and changes in internal egg (Burnham et al., 2003b) and eggshell (Branton et al., 1997) quality. The S6 strain of MG, one of the more virulent strains in the field (Levisohn et al., 1986) , has been noted to lead to a deterioration in egg quality upon infecting the genital tract of chickens (Pruthi and Kharole, 1981) . Likewise, Parker et al. (2003) reported that an S6 strain of MG inoculation at 20 weeks of age (woa) decreased uterine weight as a percentage of BW and decreased infundibulum, magnum, and total oviduct length in commercial layers. Furthermore, Peebles et al. (2006) noted that liver lipid concentration was decreased in response to an S6 strain of MG inoculation at 45 woa. Vaccines that can be used against virulent field-strain infections are inactivated oil-emulsion bacterins (MGBac) and live attenuated vaccines (Kleven, 2008) . The live attenuated vaccine strains of MG that are now commercially available are F (FMG), ts-11 (ts11MG), and 6/85.
The inoculation of pullets with FMG may lead to a subsequent delay in the onset of lay (Burnham et al., 2002a) . However, earlier studies have shown that vaccinating pullets with FMG can reduce egg production losses in response to field-strain MG infections (Carpenter et al., 1981) . Burnham et al. (2002b) found that vaccinating pullets at 12 woa resulted in increased incidences of fatty liver hemorrhagic syndrome and ovarian follicular regression. This vaccination regimen also resulted in a decrease in the relative contributions of the isthmus and vagina to the total mass of the oviduct and the relative contribution of the magnum to the total length of the oviduct. It was suggested that these were the result of mutual disturbances in the functions of the liver, ovary, and oviduct. Furthermore, in a later study, Burnham et al. (2003a) concluded that FMG may exert a chronic suppressive effect on the synthesis of proteins and lipids in the livers of commercial layers.
It has been suggested that prelay vaccinations of either ts11MG or the 6/85 strain of MG (Viscione et al., 2009 ) applied in conjunction with an overlay vaccination of FMG during lay may provide effective continual protection for commercial flocks against field strain MG infections, while avoiding the adverse effects of an individual prelay vaccination of FMG on performance . Vance et al. (2009) reported that the vaccination of layers with ts11MG at 10 woa increased vagina length as a percentage of total oviduct length, but had no influence on any of the other gross characteristics of their digestive and reproductive tracts. Similarly, Viscione et al. (2009) reported no effects of a 6/85 strain of MG vaccination at 10 woa on the gross characteristics of the reproductive and digestive organs of layers. Although MGBac has been reported to provide protection for chickens against virulent MG challenges up to 7 wk postvaccination (Hildebrand et al., 1983; Hildebrand, 1985) , there are no data available concerning the prelay use of MGBac on the digestive and reproductive organ characteristics of commercial laying hens. Furthermore, no information has been published concerning these possible effects in response to the combinatorial prelay use of ts11MG and MGBac in conjunction with a subsequent FMG overlay vaccination administered after postpeak egg production. Therefore, the objective of this study was to determine the effects of ts11MG and MGBac vaccines, administered individually and in combination before lay (10 woa) with and without a subsequent FMG vaccination overlay after peak egg production (45 woa), on various digestive and reproductive organ characteristics of commercial laying hens.
MATERIALS AND METHODS

Research Design and Treatments
Two trials were conducted using commercially available MG vaccines that were administered in accordance with their manufacturer's recommendations. The titers of each vaccine in each trial were reported in a companion article by Jacob et al. (2014) . In each trial, the following treatments were utilized at 10 woa: Treatment 1 received no vaccination (Double Control); treatment 2 consisted of birds that were vaccinated with 0.5 mL of MGBac (MG-Bac, Fort Dodge Animal Health, Overland Park, KS) via i.m. injection into the left breast muscle using a 1 mL tuberculin needle and syringe (MGBac/10); treatment 3 consisted of birds that were eye-drop-vaccinated in the left eye with approximately 30 μL of ts11MG (Mycoplasma Gallisepticum Vaccine, Merial Select, Gainesville, GA) (ts11MG/10); and in treatment 4, birds were vaccinated with both ts11MG and MGBac according to the previously described methods of administration for each (ts11MG+MGBac/10).
Four replicate isolation units containing 10 birds, were assigned to each treatment group, so that there was a total of 40 birds per treatment group. At 45 woa, the birds in 2 replicate pens in each treatment group were vaccinated with a laboratory stock of high-passage-FMG (99th passage above the unknown passage level), thereby increasing the number of the treatments to 8. A 24-h broth culture of FMG was generated in Frey's broth medium (Frey et al., 1968) , and 20 μL of the overnight culture was applied via eye-drop inoculation. The FMG overlaid counterparts of all the above treatments were represented as Control+FMG/45; MGBac/10+FMG/45; ts11MG/10+FMG/45; and ts11MG+MGBac/10+FMG/45, respectively. Handling procedures were implemented to minimize risk of cross-contamination.
Pullet and Layer Management
All procedures of bird handling and management were approved by the USDA-ARS Institutional Animal Care and Use Committee. One-day-old Hy-Line W-36 commercial layer chicks used in each trial were obtained from a MG-and Mycoplasma synoviae-free commercial source. Housing conditions and chick management during the pullet phase were as described by Peebles et al. (2015) . Further lighting details during the pullet phase were as described by Jacob et al. (2014) .
In both trials, groups of 11 birds each were randomly selected at 9 woa and transferred to temperaturecontrolled, negative-pressure fiberglass biological isolation units in an environmentally controlled diseaseisolation facility (Branton and Simmons, 1992) , and were maintained under conditions described by Evans et al. (2012) . Throughout the entire duration of the trials, air temperature within the isolation units was maintained at 23
• C. The locations of the treatment groups within the isolation facility were rearranged after trial 1 to assure randomization between trials.
Four birds per unit were bled and the serum was used for the detection of any MG infections via serum plate agglutination tests at the time of placement in the isolation units. In addition, following the procedure described in detail by Jacob et al. (2014) , further MG screening was performed on all birds at 9, 45, and 52 woa using choanal cleft swabs to test for the presence or absence of MG according to treatment by PCR-based DNA detection techniques (Kleven, 2008) .
When the total daily egg production of the birds reached 10%, one bird in each pen was randomly selected and killed to reduce the total number of hens to 10 per unit (stocking density: 0.116 m 2 /bird) for the duration of each trial. Beginning at 18 woa, the artificial lighting schedule was increased by 15 min/wk until a cycle of 16 h 15 min light and 7 h 45 min dark was achieved as previously described (Branton et al., 2002) . Layers were maintained on that schedule through the remainder of the experiment.
Pullet and Layer Diets
For the duration of each trial, birds had ad libitum access to feed and water. In the pullet and layer phases, all birds received standard diets that met or exceeded National Research Council (1994) recommendations. The diets as previously described by Burnham et al. (2002a) , were formulated according to the age of the birds, with 5 types of diets being provided over the course of each trial as follows: starter, 0 to 6 woa; grower, 6 to 12 woa; developer, 12 to 18 woa; prelay, 18 woa to onset of lay; and layer, onset of lay to end of experiment.
Data Collection
At 55 woa in both trials, 4 tagged birds from each replicate pen were killed by cervical dislocation following an overnight (12-h) fast. The birds were subsequently weighed and select internal organs were harvested. The following parameters were determined: incidence of fatty liver hemorrhagic syndrome; mature ovarian follicle numbers (those that were ≥ 12 mm in diameter); absolute liver, ovary, total oviduct, infundibulum, magnum, isthmus, uterus, vagina, total small intestine, duodenum, jejunum, and ileum weights; and lengths of the total oviduct, infundibulum, magnum, isthmus, uterus, vagina, total small intestine, duodenum, jejunum, and ileum. Relative liver, ovary, total oviduct, and total small intestine weights were expressed as percentages of BW. The weights of the 5 portions of the oviduct were expressed as percentages of BW and of total oviduct weight, and the weights of the 3 portions of the small intestine were likewise expressed as percentages of BW and of total small intestine weight. In addition, the lengths of the 5 portions of the oviduct were expressed as percentages of total oviduct length, and the lengths of the 3 portions of the small intestine were expressed as percentages of total small intestine length.
The livers of all sampled birds in each trial were examined for the incidence of fatty liver hemorrhagic syndrome by the same observer. Incidence of fatty liver hemorrhagic syndrome was calculated as a percentage of those exhibiting fatty liver hemorrhagic syndrome to any degree among those that were sampled in each replicate unit (Burnham et al., 2002b; Peebles et al., 2006) . A caliper was used to measure follicle diameter, and based on mature ovarian follicle numbers, a categorical number of 0 (zero mature follicles) to 7 (seven mature follicles; maximum number recorded) was assigned to each bird (Burnham et al., 2002b; Peebles et al., 2006) . The average number of mature ovarian follicles in the birds sampled from each replicate unit was also calculated.
Statistical Analysis
Designating trial as a blocking factor, a generalized randomized complete block experimental design was used. Data from the 2 trials were pooled and analyzed together, with trial considered as a random effect. Individual sample data within each of the replicate units were averaged before analysis. All data were analyzed using the MIXED procedure of SAS (SAS Institute, 2012) . Least squares means were compared in the event of significant effects. F tests were performed to evaluate treatment effects, and comparison of least squares means was achieved using t tests (Littell et al., 2006) . Effects and differences among least squares means were considered significant at P ≤ 0.05.
RESULTS
For both trials, serological screenings at 9 woa indicated that the birds had no previous exposure to MG. Furthermore, PCR assays at 9, 45, and 52 woa revealed no evidence for the presence of MG-DNA in those treatments not receiving ts11MG vaccination or the FMG overlay. However, the presence of MG-DNA was detected in those that received ts11MG or FMG, and evidence for its presence was not different between those groups that received ts11MG alone or in combination with MGBac (Jacob et al., 2014) . There were treatment main effects for total small intestine weight as a percentage of BW (P ≤ 0.0001, Table 1); vagina weight as a percentage of total oviduct weight (P = 0.0128, Table 2 ); and for weights of the duodenum, jejunum, and ileum as percentages of BW (P ≤ 0.0001, Table 3 ). Except for the aforementioned effects noted, no other parameters investigated were affected by the imposed treatments. The treatment means for fatty liver hemorrhagic syndrome incidence, mature ovarian follicle numbers, BW, liver weight as a percentage of BW, total small intestine weight as a percentage of BW, and the relative weights (percentages of BW) of the ovary and total oviduct are provided in Table 1 . The treatment means for the weights of the infundibulum, magnum, isthmus, uterus, and vagina as percentages of total oviduct weight are provided in Table 2 , and the Table 1 . Mean percentage incidence of fatty liver hemorrhagic syndrome (FLHS); mature ovarian follicle numbers (MOFN); BW; and relative weights of the liver (RLW), ovary (ROVAW), total oviduct (ROVIW), and total small intestine (RSIW), as percentages of BW, in the different treatment groups across trials 1 and 2. 4.13 ± 0.357 47.6 ± 1.07 11.6 ± 0.75 28.6 ± 1.14 6.81 c ± 0.594 MGBac/10+FMG/45 3.78 ± 0.357 48.6 ± 1.07 11.5 ± 0.75 28.4 ± 1.14 6.12 c ± 0.594 ts11MG/10+FMG/45 3.80 ± 0.348 49.1 ± 1.05 12.5 ± 0.75 27.2 ± 1.13 6.92 b,c ± 0.616 ts11MG+MGBac/10+FMG/45 3.02 ± 0.357 47.9 ± 1.07 12.1 ± 0.75 30.5 ± 1.14 6.63 c ± 0.594 a-c Means within a column with no common superscript differ significantly (P ≤ 0.05). 1 Samples from 4 birds in each of 2 replicate units within each of 2 replicate trials (N = 16) were used to calculate treatment means.
Treatment --------------(%)--------------
2 Treatments included Double Control, MG-Bacterin at 10 wk (MGBac/10), ts-11 MG at 10 wk (ts11MG/10), ts-11 MG and MG-Bacterin together at 10 wk (ts11MG+MGBac/10, Control and FMG at 45 wk (Control+FMG/45), MG-Bacterin at 10 wk and FMG at 45 wk (MGBac/10+FMG/45), ts-11 MG at 10 wk and FMG at 45 wk (ts11MG/10+FMG/45), and ts-11 MG and MG-Bacterin at 10 wk and FMG at 45 wk (ts11MG+MGBac/10+FMG/45. relative weights of the duodenum, jejunum, and ileum as percentages of BW are provided in Table 3 .
In the birds that received an FMG overlay at 45 woa, total small intestine weight as a percentage of BW in the Control+FMG/45 and ts11MG+MGBac/10+FMG/45 treatment groups was higher than that in the MGBac/10+FMG/45 and ts11MG/10+FMG/45 treatment groups, and total small intestine weight as a percentage of BW in all 4 treatment groups that received an FMG overlay vaccination during lay was higher than all of the 4 pre-lay treatment counterparts (Table 1) . Likewise, the responses of the relative weights (percentages of BW) of each of the 3 components of the small intestine (duodenum, jejunum, and ileum) to the applied treatments were similar to that of the relative weight of the entire small intestine (Table 3 ). The weights of the duodenum and ileum as percentages of BW in birds overlay vaccinated with FMG at 45 woa were higher than all of the counterpart pre-lay treatments. This was also true for jejunum weight as a percentage of BW, except that the MGBac/10 treatment group was not different from the ts11MG/10+FMG/45 group, and the ts11MG/10 group was not different from the MGBac/10+FMG/45 and the ts11MG/10+FMG/45 groups. For the relative weights of all 3 small intestinal components, as percentages of BW, there was no difference among the treatment groups that did not receive an FMG overlay. Conversely, in birds that did receive an FMG overlay, the relative weights of the 3 small intestinal components, as percentages of BW, were higher in response to the ts11MG+MGBac/10+FMG/45 treatment in comparison to the MGBac/10+FMG/45 and ts11MG/10+FMG/45 treatments, with the Control+FMG/45 treatment being intermediate. Furthermore, for ileum weight as a percentage of BW, the Control+FMG/45 group was higher than the ts11MG/10+FMG/45 group (Table 3) . Table 3 . Mean duodenum (RDUOW), jejunum (RJEJW), and ileum weights (RILEW), as percentages of BW, in the different treatment groups across trials 1 and 2. a-e Means within a column with no common superscript differ significantly (P ≤ 0.05). 1 Samples from 4 birds in each of 2 replicate units within each of 2 replicate trials (N = 16) were used to calculate treatment means.
2 Treatments included Double Control, MG-Bacterin at 10 wk (MGBac/10), ts-11 MG at 10 wk (ts11MG/10), ts-11 MG and MG-Bacterin together at 10 wk (ts11MG+MGBac/10, Control and FMG at 45 wk (Control+FMG/45), MG-Bacterin at 10 wk and FMG at 45 wk (MGBac/10+FMG/45), ts-11 MG at 10 wk and FMG at 45 wk (ts11MG/10+FMG/45), and ts-11 MG and MG-Bacterin at 10 wk and FMG at 45 wk (ts11MG+MGBac/10+FMG/45.
However, vagina weight as a percentage of total oviduct weight was higher in birds belonging to the ts11MG/10 treatment group in comparison to those in all the other treatment groups, except for those in the Double Control and MGBac/10 groups. In turn, vagina weight as a percentage of total oviduct weight in the Double Control and MGBac/10 birds was higher than the Control+FMG/45, MGBac/10+FMG/45, and ts11MG+MGBac/10+FMG/45 birds, with the ts11MG+MGBac/10 and ts11MG/10+FMG/45 birds being intermediate (Table 2) .
DISCUSSION
The cellular invasiveness of MG organisms (Winner et al., 2000) and the sequestration of MG from the liver (Sahu and Olsen, 1976) , would indicate that MG is capable of interfering with hepatic protein metabolic processes. Manafi et al. (2015) found that the posthatch inoculation of broilers with an undisclosed strain of pathogenic MG led to a reduction in their BW and serum total protein levels, and was further associated with liver necrosis and inflammatory cell infiltration, as well as vacuolar hepatocyte degeneration. Likewise, Peebles et al. (2006) reported that the posthatch inoculation of layers with the S6 strain of MG, a virulent field-strain of MG, decreased their liver lipid concentrations. F-strain MG is pathogenic to turkeys, but was the first live attenuated vaccine approved and licensed for the exclusive use in commercial layers (Branton et al., 1999) . Burnham et al. (2002b) found that the incidence of fatty liver hemorrhagic syndrome increased in layers that had been vaccinated with FMG during the pullet period, and it was later suggested by Burnham et al. (2003a) that FMG may suppress hepatic protein and lipid synthesis in layers.
Conversely, the treatments applied in the current study, which included the vaccination of FMG during lay alone or in combination with prelay vaccinations of ts11MG and MGBac, had no effect on hen BW, liver weight as a percentage of BW, or fatty liver hemorrhagic syndrome incidence. Similarly, Viscione et al. (2009) noted no effect of an FMG vaccination at 45 woa on liver weight as a percentage of BW, fatty liver hemorrhagic syndrome incidence, or liver lipid and moisture concentrations. Vance et al. (2009) likewise noted no effects of ts11MG alone at 10 woa, FMG alone at 45 woa, or the combination of the 2 vaccination regimens on the same liver parameters examined by Viscione et al. (2009) . Furthermore, in a companion article, Peebles et al. (2015) observed no effect of these same treatments on the serum total proteins or serum lipids of these birds, except for an opposite effect of ts11MG on serum total protein levels at 33 and 43 woa. Peebles et al. (2009) also did not observe a vaccination treatment effect involving ts11MG at 10 woa with or without an FMG overlay at 45 woa on the plasma protein concentrations of layers. The treatment effect on serum total proteins observed by Peebles et al. (2015) is, therefore, distinctive and in contrast to the previous results of Peebles et al. (2009) . However, although no previous work has confirmed that ts11MG invasively colonizes the liver, because histological analyses of the livers of the birds in the current study were not performed, the presence of histopathological lesions in their livers cannot be precluded.
Although the treatments applied in this study were shown not to affect liver weight as a percentage of BW or fatty liver hemorrhagic syndrome incidence, the digestive system of the birds was shown to be affected through observed effects on the weights of the total small intestine, duodenum, jejunum, and ileum as percentages of BW. Despite the fact that the proportional weights and lengths of the duodenum, jejunum, and ileum in the small intestine did not change in response to treatment, their weights as percentages of BW did. In general, an FMG vaccination during lay at 45 woa led to increases in the weights of the total small intestine, duodenum, jejunum, and ileum as percentages of BW, despite singular or combinatorial prelay vaccinations of ts11MG and MGBac. Conversely, Viscione et al. (2009) reported that an FMG vaccination at 45 woa had no effect on the total and segmental weights, lengths, and histologies of the small intestine. Vance et al. (2009) also noted no effect of a 45 woa FMG vaccination on the same small intestine parameters that were investigated by Viscione et al. (2009) . Therefore, the observed relative enlargements of the small intestine and its various segments in response to an FMG vaccination imposed at 45 woa is unique to this study.
However, except for a noted decrease in ileum weight as a percentage of BW in response to the ts11MG/10+FMG/45 treatment, these results further indicate that use of ts11MG as a prelay vaccine alone or in combination with MGBac, with or without an overlay vaccination of FMG at 45 woa, has no effect on the gross characteristics of the digestive organs of layers. Similar to the current study, Vance et al. (2009) found no effects of ts11MG alone at 10 woa or in combination with FMG at 45 woa on small intestine histology as well as the small intestinal parameters that were investigated in this study. More specifically, the present results further indicate that the use of MGBac as a prelay vaccine alone or in combination with ts11MG, with or without an overlay vaccination of FMG at 45 woa, has no effect on the gross characteristics of the digestive organs. This result is novel in light of the fact that the effects of an MGBac vaccination administered during the pullet period on the digestive organs of mature layers have not been previously investigated. However, it is interesting to note that among the group of birds that were later vaccinated with FMG at 45 woa, the weights of the total small intestine, duodenum, jejunum, and ileum as percentages of BW were lower in those that were administered either ts11MG or MGBac individually in comparison to those that received the 2 vaccines as a combination during the pullet period.
The isolated treatment effect on vagina weight as a percentage of total oviduct weight was the only one observed for the reproductive system of the birds in the current study. It showed that vagina weight as a percentage of total oviduct weight was reduced overall by the vaccination of FMG at 45 woa. The exception to this was if an FMG vaccination was preceded by an individual ts11MG vaccination. This suggests that when administered at 45 woa, FMG may reduce the relative contribution of the vagina to total oviduct weight, but that a ts11MG vaccination at 10 woa may help to alleviate this effect. From another perspective, these results also showed that a subsequent FMG vaccination at 45 woa reduced vagina weight as a percentage of total oviduct weight in birds that had been vaccinated with ts11MG and MGBac at 10 woa. Viscione et al. (2009) found that an FMG vaccination at 45 woa had no effect on any of the reproductive organ characteristics that were examined in the current study including vagina weight as a percentage of total oviduct weight. Also, like Viscione et al. (2009) , Vance et al. (2009) observed no effect of an FMG vaccination at 45 woa on the reproductive organ characteristics that were examined in the current study, except that an FMG vaccination did affect the vagina. Vance et al. (2009) noted in birds vaccinated with ts11MG at 10 woa, that vagina length as a percentage of total oviduct length was reduced if they were later vaccinated with FMG at 45 woa. Upon consideration of the results of this study and that of Vance et al. (2009) , it is suggested that in birds having been vaccinated with ts11MG at 10 woa, that the proportional length or weight of their vagina may be reduced if they are subsequently vaccinated with FMG at 45 woa. However, these possible effects appear to be inconsequential to layer performance, as previous results in earlier companion reports have shown that a prelay MGBac vaccination alone or in combination with ts11MG has no subsequent adverse effects on the performance characteristics (Jacob et al., 2014) or the internal egg and eggshell characteristics of commercial layer chickens.
In conclusion, the current results of this study suggest that a prelay MGBac vaccination does not have any additional effects on the digestive or reproductive parameters of the commercial layers that were examined at the ages specified, and because noted changes in the small intestine and oviduct in response to the vaccine regimens applied in this study were apparently incidental with regard to layer performance, a prelay vaccination regimen using ts11MG alone or in combination with MGBac may be safely used to protect commercial laying hens against possible field strain MG infections.
